MorphoSys AG (ETR:MOR) received a €77.00 ($90.59) target price from investment analysts at Independent Research GmbH in a research note issued to investors on Monday. The firm presently has a “buy” rating on the stock.

A number of other brokerages have also weighed in on MOR. Berenberg Bank set a €68.00 ($80.00) price objective on MorphoSys AG and gave the company a “buy” rating in a research note on Thursday, May 25th. Commerzbank Ag set a €76.00 ($89.41) target price on MorphoSys AG and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) target price on MorphoSys AG and gave the stock a “neutral” rating in a research report on Friday. HSBC Holdings plc set a €59.00 ($69.41) price objective on MorphoSys AG and gave the company a “neutral” rating in a research report on Friday, July 14th. Finally, Deutsche Bank AG set a €90.00 ($105.88) price objective on MorphoSys AG and gave the company a “buy” rating in a research report on Monday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. MorphoSys AG presently has an average rating of “Buy” and a consensus target price of €69.57 ($81.85).

MorphoSys AG (ETR MOR) opened at 58.909 on Monday. The firm’s market capitalization is €1.69 billion. MorphoSys AG has a 52-week low of €35.72 and a 52-week high of €70.90. The firm has a 50-day moving average price of €62.87 and a 200 day moving average price of €57.10.

COPYRIGHT VIOLATION WARNING: “MorphoSys AG (ETR:MOR) PT Set at €77.00 by Independent Research GmbH” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/morphosys-ag-etrmor-pt-set-at-77-00-by-independent-research-gmbh.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.